Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
V501 (Gardasil) Immunogenicity in Japanese Boys
NCT02576054Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2015
- Primary completion
- Aug 2018
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection and condyloma acuminata, sponsored by Merck & Co. Primary endpoints: Percentage of Participants With Seroconversion for HPV Types 6, 11, 16, and 18 at Month 7, Percentage of Participants With Elevated Oral Temperature (>=37.5° C) at Day 5 and 4 more. Started Nov 2015; status: completed.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infectioncondyloma acuminata
Beyond the preview
Go deeper on NCT02576054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02576054.